ArticleBlood2024

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.

Shirley D'Sa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.